610 related articles for article (PubMed ID: 25759505)
1. Heparan sulfate-dependent enhancement of henipavirus infection.
Mathieu C; Dhondt KP; Châlons M; Mély S; Raoul H; Negre D; Cosset FL; Gerlier D; Vivès RR; Horvat B
mBio; 2015 Mar; 6(2):e02427. PubMed ID: 25759505
[TBL] [Abstract][Full Text] [Related]
2. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.
Yun T; Park A; Hill TE; Pernet O; Beaty SM; Juelich TL; Smith JK; Zhang L; Wang YE; Vigant F; Gao J; Wu P; Lee B; Freiberg AN
J Virol; 2015 Jan; 89(2):1242-53. PubMed ID: 25392218
[TBL] [Abstract][Full Text] [Related]
3. Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes.
Bradel-Tretheway BG; Zamora JLR; Stone JA; Liu Q; Li J; Aguilar HC
J Virol; 2019 Jul; 93(13):. PubMed ID: 30971473
[TBL] [Abstract][Full Text] [Related]
4. Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage.
Negrete OA; Chu D; Aguilar HC; Lee B
J Virol; 2007 Oct; 81(19):10804-14. PubMed ID: 17652392
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided mutagenesis of Henipavirus receptor-binding proteins reveals molecular determinants of receptor usage and antibody-binding epitopes.
Oguntuyo KY; Haas GD; Azarm KD; Stevens CS; Brambilla L; Kowdle SS; Avanzato VA; Pryce R; Freiberg AN; Bowden TA; Lee B
J Virol; 2024 Mar; 98(3):e0183823. PubMed ID: 38426726
[TBL] [Abstract][Full Text] [Related]
6. The changing face of the henipaviruses.
Croser EL; Marsh GA
Vet Microbiol; 2013 Nov; 167(1-2):151-8. PubMed ID: 23993256
[TBL] [Abstract][Full Text] [Related]
7. Hendra and Nipah infection: emerging paramyxoviruses.
Aljofan M
Virus Res; 2013 Nov; 177(2):119-26. PubMed ID: 23954578
[TBL] [Abstract][Full Text] [Related]
8. Nipah and Hendra Virus Nucleoproteins Inhibit Nuclear Accumulation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT2 by Interfering with Their Complex Formation.
Sugai A; Sato H; Takayama I; Yoneda M; Kai C
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835499
[TBL] [Abstract][Full Text] [Related]
9. Sequence basis for selectivity of ephrin-B2 ligand for Eph receptors and pathogenic henipavirus G glycoproteins.
Narayanan KK; Amaya M; Tsang N; Yin R; Jays A; Broder CC; Shukla D; Procko E
J Virol; 2023 Nov; 97(11):e0062123. PubMed ID: 37931130
[TBL] [Abstract][Full Text] [Related]
10. Third Helical Domain of the Nipah Virus Fusion Glycoprotein Modulates both Early and Late Steps in the Membrane Fusion Cascade.
Zamora JLR; Ortega V; Johnston GP; Li J; André NM; Monreal IA; Contreras EM; Whittaker GR; Aguilar HC
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669342
[TBL] [Abstract][Full Text] [Related]
11. Hendra and Nipah viruses: why are they so deadly?
Marsh GA; Wang LF
Curr Opin Virol; 2012 Jun; 2(3):242-7. PubMed ID: 22483665
[TBL] [Abstract][Full Text] [Related]
12. Henipavirus membrane fusion and viral entry.
Aguilar HC; Iorio RM
Curr Top Microbiol Immunol; 2012; 359():79-94. PubMed ID: 22427111
[TBL] [Abstract][Full Text] [Related]
13. Developments towards effective treatments for Nipah and Hendra virus infection.
Bossart KN; Broder CC
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):43-55. PubMed ID: 16441208
[TBL] [Abstract][Full Text] [Related]
14. Hendra and Nipah viruses: pathogenesis and therapeutics.
Eaton BT; Broder CC; Wang LF
Curr Mol Med; 2005 Dec; 5(8):805-16. PubMed ID: 16375714
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome Profiling of the Virus-Induced Innate Immune Response in Pteropus vampyrus and Its Attenuation by Nipah Virus Interferon Antagonist Functions.
Glennon NB; Jabado O; Lo MK; Shaw ML
J Virol; 2015 Aug; 89(15):7550-66. PubMed ID: 25972557
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Genomic Characterization of a Novel Henipavirus, Angavokely Virus, from Fruit Bats in Madagascar.
Madera S; Kistler A; Ranaivoson HC; Ahyong V; Andrianiaina A; Andry S; Raharinosy V; Randriambolamanantsoa TH; Ravelomanantsoa NAF; Tato CM; DeRisi JL; Aguilar HC; Lacoste V; Dussart P; Heraud JM; Brook CE
J Virol; 2022 Sep; 96(18):e0092122. PubMed ID: 36040175
[TBL] [Abstract][Full Text] [Related]
17. Favipiravir (T-705) protects against Nipah virus infection in the hamster model.
Dawes BE; Kalveram B; Ikegami T; Juelich T; Smith JK; Zhang L; Park A; Lee B; Komeno T; Furuta Y; Freiberg AN
Sci Rep; 2018 May; 8(1):7604. PubMed ID: 29765101
[TBL] [Abstract][Full Text] [Related]
18. Hendra and nipah infection: pathology, models and potential therapies.
Vigant F; Lee B
Infect Disord Drug Targets; 2011 Jun; 11(3):315-36. PubMed ID: 21488828
[TBL] [Abstract][Full Text] [Related]
19. Nipah virus attachment glycoprotein stalk C-terminal region links receptor binding to fusion triggering.
Liu Q; Bradel-Tretheway B; Monreal AI; Saludes JP; Lu X; Nicola AV; Aguilar HC
J Virol; 2015 Feb; 89(3):1838-50. PubMed ID: 25428863
[TBL] [Abstract][Full Text] [Related]
20. Animal challenge models of henipavirus infection and pathogenesis.
Geisbert TW; Feldmann H; Broder CC
Curr Top Microbiol Immunol; 2012; 359():153-77. PubMed ID: 22476556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
